IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Lipocine
Inc. and Reminds Investors with Losses to Contact the Firm
Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Lipocine Inc. (“Lipocine” or the
“Company”) (Nasdaq: LPCN). Investors who purchased or otherwise acquired shares between June 30, 2015 and June 28, 2016 inclusive
(the “Class Period”), are encouraged to contact the Firm prior to the August 30, 2016 lead plaintiff motion deadline.
If you purchased shares of Lipocine during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101
Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may
choose to take no action and remain a passive class member.
According to the complaint, during the Class Period the Company made false and/or misleading statements and/or failed to
disclose that: Lipocine’s filing of its New Drug Application to the U.S. Food and Drug Administration for LPCN 1021 (the Company’s
lead product candidate) contained deficiencies; and as a result, Lipocine’s statements about its business and operations were false
and misleading and/or lacked a reasonable basis. When this information entered the market, investors suffered losses.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.
Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160706006126/en/